European Regulators Back Incyte's Atopic Dermatitis Cream for Approval
INCY sits 64% above its 52-week low of $66.83.
Summary
The European Medicines Agency (EMA) has recommended approval for Incyte's Opzelura cream to treat moderate atopic dermatitis in adults. This positive opinion, based on Phase 3 studies, paves the way for Opzelura to become the first steroid-free topical treatment option in the EU for patients who have failed standard therapies. If approved by the European Commission, this would significantly expand the market for a key Incyte product, marking its second indication in the EU. This news adds to a strong recent pipeline of positive developments for Incyte, including the recent acquisition of Vega Therapeutics and FDA approval for Jakafi XR.
At the time of this announcement, INCY was trading at $109.36 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $21.5B. The 52-week trading range was $66.83 to $112.29. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.